The Bitter Pill: Pharma Lobby Myths vs Scientific Proof — Generics Equally Good, Up to 80% Cheaper

By Suresh Unnithan

In India, where soaring healthcare costs can devastate families financially, both central and state governments have launched numerous initiatives to make essential medicines more accessible and affordable. Programs like the Pradhan Mantri Jan Arogya Yojana (PMJAY) and the Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP), popularly known as Jan Aushadhi Kendras, offer generic drugs at up to 80% lower prices than branded equivalents. These efforts aim to curb out-of-pocket expenses, which constitute 62-69% of total healthcare spending in the country. However, these well-intentioned schemes are often undermined by a collusion between medical practitioners and pharmaceutical companies, who perpetuate myths about generic drugs’ inferiority to protect profits from branded products. This resistance not only misguides patients but also erodes public trust in government programs. A recent study by Kerala-based hepatologist Dr. Cyriac Abby Philips has debunked these claims through scientific testing, while voices like that of Dr. Sailajamma, a retired ESI services doctor, highlight the real-world pushback faced by those advocating for generics. This article explores how patients are being duped, the systemic sabotage of affordability initiatives, and the evidence supporting generics as a viable, high-quality alternative.

The Undermining of Government Initiatives: A Collusion at Play

Generic drugs are chemically identical to branded ones, featuring the same active ingredients, dosage, strength, and administration method. They gain approval from bodies like the Central Drugs Standard Control Organization (CDSCO) post-patent expiration, enabling production at lower costs without hefty research or marketing budgets. Through PMBJP, the central government has established over 10,000 Jan Aushadhi stores nationwide, providing more than 2,000 medicines and 300 surgical items at steep discounts. State governments, too, have complemented these with local schemes, such as Kerala’s Karunya Community Pharmacies or Tamil Nadu’s Amma Pharmacies, which similarly prioritize generics to ease the burden on low-income households.

Despite this, a majority of doctors fail to direct patients toward these outlets, often prescribing branded drugs instead. This stems from deep-rooted biases, aggressive pharmaceutical marketing, and financial incentives like sponsorships, free samples, and conference perks offered by drug companies. Pharma giants torpedo government plans by lobbying against mandatory generic prescribing and spreading unfounded doubts about quality. For example, Dr. Sailajamma, who retired from Employees’ State Insurance (ESI) services, encountered outright hostility from pharmaceutical dealers for her steadfast advocacy of PMBJP shops. “I always suggested patients get drugs from PMBJP shops and was strict in my approach,” she shared. “I insisted on purchases from those outlets and never reimbursed bills from private medical shops for medicines available there.” Her principled stance, aimed at saving patients money, drew backlash, illustrating how the system punishes those who prioritize affordability over industry interests.

To truly contain medicinal costs and protect consumers’ pockets, initiatives like Dr. Sailajamma’s must be promoted widely and, ideally, made mandatory. Medical practitioners who habitually prescribe branded medicines over generics should face penalties, as per existing guidelines from the Medical Council of India (MCI), which mandate generic prescribing but are routinely ignored. According to Dr. Sailajamma, the medicines distributed through PMBJP shops are “as good as any branded drug from top-class pharma companies, and in certain cases even better,” based on her extensive clinical experience.

Instances of Deception: How the Common Man is Duped

The duping of patients extends beyond mere prescription preferences, manifesting in various exploitative practices that inflate costs and exploit vulnerability. One common tactic is overprescription: Doctors, influenced by pharma ties, often recommend unnecessary branded antibiotics or supplements, even for minor ailments, leading to bills that balloon by 30-50%. For instance, a simple viral fever might result in a prescription for expensive branded painkillers and vitamins, when generics or no medication would suffice, duping patients into believing more drugs equal better care.

Another widespread issue is hospital-pharmacy tie-ups, where private hospitals direct patients exclusively to in-house or affiliated pharmacies stocking only high-margin branded drugs. In rural areas like Kollam, Kerala, patients with limited options end up paying premiums without knowing affordable Jan Aushadhi alternatives exist nearby. Similarly, during emergencies, families are pressured into buying overpriced injectables or IV fluids from hospital counters, often at 2-3 times the market rate, under the guise of “immediate availability” or “superior quality.”

Misinformation about side effects further deceives the common man. Pharma reps highlight rare, isolated incidents of generic batch failures—while conveniently ignoring similar issues with brands—to scare doctors and patients alike. In chronic care, such as diabetes management, patients are told generics cause “unpredictable blood sugar fluctuations,” prompting them to stick with costly brands like branded metformin at Rs 100-150 per strip versus Rs 20 for the generic. A 2023 Indian Council of Medical Research report exposed how these practices contribute to overprescription, pushing families into debt cycles.

In Kerala, with its high healthcare literacy, these deceptions still prevail. Residents in districts like Kollam and Ernakulam, reliant on local clinics, often pay inflated prices for branded hypertension drugs, unaware that state-backed outlets offer equivalents at a fraction of the cost. Past scandals, such as the 2020-2025 reports of 206 prosecutions for substandard Jan Aushadhi batches, are exaggerated by media and pharma lobbies to fuel doubts, despite these being a minuscule fraction of total distributions and comparable to branded failures.

Debunking the Myths: Evidence from Dr. Cyriac Abby Philips’ Study

Challenging this ecosystem of deceit is Dr. Cyriac Abby Philips, a hepatologist from Ernakulam, Kerala, popularly known as “The Liver Doc” (@TheLiverDoc on X). Through the Citizen’s Generic vs. Branded Drugs Quality Project under the Mission for Ethics and Science in Healthcare (MESH)—a crowdfunded, independent initiative—his team tested 131 samples of 22 common medicines across categories like heart disease, diabetes, and liver disorders. Sourced from branded, generic, and government outlets like Jan Aushadhi and Kerala Medical Services Corporation Ltd (KMSCL), the samples were analyzed at a US FDA-accredited lab against Indian Pharmacopoeia standards.

The findings, released in early January 2026, were resounding: All samples passed, with generics averaging 99.10% drug content (within the 90-110% norm) compared to branded drugs’ 101.35%. Jan Aushadhi options were the cheapest for 82% of medicines, slashing costs by up to 49% overall. For drugs like rifaximin, branded versions cost 5-14 times more without superior quality. A patient story from Dr. Philips’ practice underscores the impact: Jithin, battling liver cirrhosis, nearly quit treatment due to branded rifaximin’s Rs 42 per tablet price but thrived on generics after overcoming initial skepticism.

The Broader Impact: Financial Strain and Health Risks

Such deceptions exact a heavy toll. High costs lead to treatment non-adherence, contributing to 50% of chronic disease failures per WHO estimates. For a low-income family, branded ursodeoxycholic acid for liver issues might cost over Rs 22,000 annually, versus under Rs 6,000 via Jan Aushadhi—savings that could cover essentials like food or education. Experts emphasize those generics perform equally well, stressing the need for affordability to ensure compliance.

Path to Reform: Promoting Equity and Accountability

To counter this, independent studies like Dr. Philips’ must be amplified, alongside stricter enforcement of generic prescribing rules. Governments should expand quality audits, penalize non-compliant doctors, and run awareness campaigns. Patients can empower themselves by questioning prescriptions, using the PMBJP app for outlet locations, and seeking second opinions. By fostering transparency and holding practitioners accountable,  the  nation can ensure healthcare equity, where quality isn’t dictated by price, and no one is duped out of affordable care.

Research by Nanditha Subhadra